Therapy Areas: Cardiovascular
Medicure wins US FDA approval for Sodium Nitroprusside Injection for cardiovascular market
14 August 2018 -

Pharmaceutical company Medicure Inc (TSXV:MPH) (OTC:MCUJF) reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the cardiovascular drug Sodium Nitroprusside Injection in 50 mg/2 ml (25 mg/ml) single dose vial (SNP).

SNP, a generic intravenous cardiovascular drug product, is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis, for producing controlled hypotension in order to reduce bleeding during surgery as well as for the treatment of acute congestive heart failure, added the company.

The company said its newly approved Sodium Nitroprusside Injection was determined by the US FDA to be therapeutically equivalent to Nitropress (Sodium Nitroprusside Injection).

In addition, the company continues to develop two additional generic versions of acute cardiovascular drugs and explore other potential development opportunities.



Related Headlines